
This Phase III open-label extension study assessed the long-term efficacy and safety of preservative-free latanoprost 0.005% eye drop cationic emulsion in adults with open-angle glaucoma or ocular hypertension. Over 15 months, treatment maintained sustained intraocular pressure reduction, improved ocular surface disease signs and symptoms, and showed good tolerability with no serious treatment-related adverse events.
Like
Save
Share